Enovis CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Enovis CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Oct 1, 2021 | $965.89M | Nov 4, 2021 |
| FY2021 | Jul 2, 2021 | $985.93M | Jul 28, 2021 |
| FY2021 | Apr 2, 2021 | $879.21M | Apr 29, 2021 |
| FY2021 | Oct 2, 2020 | $805.93M | Nov 4, 2021 |
| FY2021 | Jul 3, 2020 | $620.36M | Jul 28, 2021 |
| FY2021 | Apr 3, 2020 | $816.36M | Apr 29, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.25B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.11B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.71B | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | $408.71M | Mar 1, 2023 |
| FY2022 | Sep 30, 2022 | $383.81M | Mar 1, 2023 |
| FY2022 | Jul 1, 2022 | $395.12M | Mar 1, 2023 |
| FY2022 | Apr 1, 2022 | $375.46M | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | $399.06M | Mar 1, 2023 |
| FY2022 | Oct 1, 2021 | $359.92M | Mar 1, 2023 |
| FY2022 | Jul 2, 2021 | $356.12M | Mar 1, 2023 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $874.08M | Feb 16, 2018 |
| FY2017 | Sep 29, 2017 | $844.51M | Feb 16, 2018 |
| FY2017 | Jun 30, 2017 | $847.96M | Feb 16, 2018 |
| FY2017 | Mar 31, 2017 | $733.63M | Feb 16, 2018 |
| FY2017 | Dec 31, 2016 | $812.41M | Feb 16, 2018 |
| FY2017 | Sep 30, 2016 | $766.52M | Feb 16, 2018 |
| FY2017 | Jul 1, 2016 | $841.12M | Feb 16, 2018 |
| FY2017 | Apr 1, 2016 | $765.71M | Feb 16, 2018 |
| FY2016 | Dec 31, 2015 | $1.06B | Feb 14, 2017 |
| FY2016 | Sep 25, 2015 | $969.14M | Feb 14, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.35B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.18B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $990.78M | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | $231.75M | Mar 1, 2023 |
| FY2022 | Sep 30, 2022 | $215.82M | Mar 1, 2023 |
| FY2022 | Jul 1, 2022 | $215.91M | Mar 1, 2023 |
| FY2022 | Apr 1, 2022 | $205.90M | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | $207.92M | Mar 1, 2023 |
| FY2022 | Oct 1, 2021 | $197.88M | Mar 1, 2023 |
| FY2022 | Jul 2, 2021 | $200.59M | Mar 1, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.18B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($825.49M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($33.26M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($13.29M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $71.66M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $42.63M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($527.65M) | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $140.20M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $151.09M | Feb 24, 2020 |
| FY2017 | Dec 31, 2016 | $128.11M | Feb 16, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.12B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($775.72M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($65.71M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($71.18M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($62.80M) | Feb 22, 2024 |
| FY2021 | Oct 1, 2021 | $63.99M | Nov 4, 2021 |
| FY2021 | Jul 2, 2021 | $75.94M | Jul 28, 2021 |
| FY2021 | Apr 2, 2021 | $61.31M | Apr 29, 2021 |
| FY2022 | Dec 31, 2020 | ($66.18M) | Mar 1, 2023 |
| FY2021 | Oct 2, 2020 | $61.93M | Nov 4, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $120.33M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $91.30M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $75.33M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $60.83M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $49.09M | Feb 22, 2024 |
| FY2021 | Oct 1, 2021 | $20.20M | Nov 4, 2021 |
| FY2021 | Jul 2, 2021 | $21.30M | Jul 28, 2021 |
| FY2021 | Apr 2, 2021 | $19.90M | Apr 29, 2021 |
| FY2022 | Dec 31, 2020 | $34.27M | Mar 1, 2023 |
| FY2021 | Oct 2, 2020 | $16.80M | Nov 4, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.07B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.03B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $830.31M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $772.91M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $665.78M | Feb 22, 2024 |
| FY2021 | Oct 1, 2021 | $334.42M | Nov 4, 2021 |
| FY2021 | Jul 2, 2021 | $337.56M | Jul 28, 2021 |
| FY2021 | Apr 2, 2021 | $305.72M | Apr 29, 2021 |
| FY2022 | Dec 31, 2020 | $515.47M | Mar 1, 2023 |
| FY2021 | Oct 2, 2020 | $278.06M | Nov 4, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $217.29M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $113.50M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $134.99M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($55.86M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $356.10M | Feb 22, 2024 |
| FY2021 | Oct 1, 2021 | $259.88M | Nov 4, 2021 |
| FY2021 | Jul 2, 2021 | $162.75M | Jul 28, 2021 |
| FY2021 | Apr 2, 2021 | $84.38M | Apr 29, 2021 |
| FY2022 | Dec 31, 2020 | $301.94M | Mar 1, 2023 |
| FY2021 | Oct 2, 2020 | $173.13M | Nov 4, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $197.38M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $180.71M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $122.22M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $105.45M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $104.24M | Feb 22, 2024 |
| FY2021 | Oct 1, 2021 | $73.60M | Nov 4, 2021 |
| FY2021 | Jul 2, 2021 | $44.64M | Jul 28, 2021 |
| FY2021 | Apr 2, 2021 | $24.54M | Apr 29, 2021 |
| FY2022 | Dec 31, 2020 | $114.79M | Mar 1, 2023 |
| FY2021 | Oct 2, 2020 | $81.58M | Nov 4, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.83B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.72B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $4.51B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $4.27B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $8.52B | Mar 1, 2023 |
| FY2021 | Oct 1, 2021 | $7.97B | Nov 4, 2021 |
| FY2021 | Jul 2, 2021 | $7.56B | Jul 28, 2021 |
| FY2021 | Apr 2, 2021 | $8.07B | Apr 29, 2021 |
| FY2021 | Dec 31, 2020 | $7.35B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $7.39B | Feb 18, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.34B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.15B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.09B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $823.45M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $3.85B | Mar 1, 2023 |
| FY2021 | Oct 1, 2021 | $3.34B | Nov 4, 2021 |
| FY2021 | Jul 2, 2021 | $3.21B | Jul 28, 2021 |
| FY2021 | Apr 2, 2021 | $3.78B | Apr 29, 2021 |
| FY2021 | Dec 31, 2020 | $3.76B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $3.90B | Feb 18, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.49B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.56B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $3.42B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $3.45B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $4.62B | Mar 1, 2023 |
| FY2021 | Oct 1, 2021 | $4.59B | Nov 4, 2021 |
| FY2021 | Jul 2, 2021 | $4.31B | Jul 28, 2021 |
| FY2021 | Apr 2, 2021 | $4.25B | Apr 29, 2021 |
| FY2021 | Dec 31, 2020 | $3.54B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $3.44B | Feb 18, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $718.30M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.69B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.06B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.98B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $1.93B | Feb 22, 2024 |
| FY2021 | Oct 1, 2021 | $3.50B | Nov 4, 2021 |
| FY2023 | Jul 28, 2021 | $92.44M | Feb 22, 2024 |
| FY2021 | Jul 2, 2021 | $3.40B | Jul 28, 2021 |
| FY2021 | Apr 2, 2021 | $3.33B | Apr 29, 2021 |
| FY2022 | Dec 31, 2020 | $1.76B | Mar 1, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.47B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($283.02M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $542.47M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $575.73M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $589.02M | Mar 1, 2023 |
| FY2021 | Oct 1, 2021 | $590.93M | Nov 4, 2021 |
| FY2021 | Jul 2, 2021 | $565.08M | Jul 28, 2021 |
| FY2021 | Apr 2, 2021 | $536.44M | Apr 29, 2021 |
| FY2021 | Dec 31, 2020 | $517.37M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $479.56M | Feb 18, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.39M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $48.17M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $36.19M | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | $24.30M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $680.25M | Mar 1, 2023 |
| FY2021 | Oct 1, 2021 | $177.48M | Nov 4, 2021 |
| FY2021 | Jul 2, 2021 | $62.31M | Jul 28, 2021 |
| FY2021 | Apr 2, 2021 | $763.65M | Apr 29, 2021 |
| FY2021 | Dec 31, 2020 | $97.07M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $109.63M | Feb 18, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.30B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.33B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $466.16M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $259.28M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $2.09B | Mar 1, 2023 |
| FY2021 | Oct 1, 2021 | $1.63B | Nov 4, 2021 |
| FY2021 | Jul 2, 2021 | $1.60B | Jul 28, 2021 |
| FY2021 | Apr 2, 2021 | $2.21B | Apr 29, 2021 |
| FY2021 | Dec 31, 2020 | $2.23B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $2.31B | Feb 18, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (20) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (14) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Mar 1, 2023 |
| FY2022 | Sep 30, 2022 | (1) | Mar 1, 2023 |
| FY2022 | Jul 1, 2022 | 1 | Mar 1, 2023 |
| FY2022 | Apr 1, 2022 | 0 | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 1, 2023 |
| FY2022 | Oct 1, 2021 | 0 | Mar 1, 2023 |
| FY2022 | Jul 2, 2021 | 0 | Mar 1, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (20) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (14) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Mar 1, 2023 |
| FY2022 | Sep 30, 2022 | (1) | Mar 1, 2023 |
| FY2022 | Jul 1, 2022 | 1 | Mar 1, 2023 |
| FY2022 | Apr 1, 2022 | 0 | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 1, 2023 |
| FY2022 | Oct 1, 2021 | 0 | Mar 1, 2023 |
| FY2022 | Jul 2, 2021 | 0 | Mar 1, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 57.19M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 55.88M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 54.60M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 54.23M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 52.08M | Mar 1, 2023 |
| FY2021 | Oct 1, 2021 | 154.78M | Nov 4, 2021 |
| FY2021 | Jul 2, 2021 | 142.34M | Jul 28, 2021 |
| FY2021 | Apr 2, 2021 | 135.60M | Apr 29, 2021 |
| FY2021 | Dec 31, 2020 | 118.50M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | 118.06M | Feb 18, 2021 |